Literature DB >> 23688709

Visual impairment and subsequent use of support services among older people: longitudinal findings from the Blue Mountains Eye Study.

Thomas Hong1, Paul Mitchell, George Burlutsky, Calvin Sze-Un Fong, Elena Rochtchina, Jie Jin Wang.   

Abstract

PURPOSE: To assess the impact of visual impairment and blindness on the incident use of community support services in the Blue Mountains Eye Study.
DESIGN: Population-based cohort.
METHODS: Of 3654 baseline participants (1992-1994), 2334, 1952, and 1149 were re-examined after 5, 10, and 15 years, respectively. Incident visual impairment was defined as subsequent development of visual impairment (visual acuity <20/40) in the better eye of subjects with best-corrected visual acuity ≥20/40 at baseline. Community support service use included regular use of Meals on Wheels, Home Care, or community nurse services. Informal support included assistance from family or friends. Discrete logistic regression models with time-dependent study and outcome variables were used to assess associations between visual impairment and subsequent use of support, adjusted for potential confounders.
RESULTS: Among participants with bilateral visual impairment at baseline, incident use of community services over 5-15 years was 41.7% compared to 19.4% in those without visual impairment at baseline (odds ratio, 1.39; 95% confidence interval, 0.54-3.60). Persons with incident bilateral visual impairment were more likely to subsequently need community support (odds ratio, 3.32; confidence interval 1.96-5.59) in 5 years, compared to persons without visual impairment during the entire follow-up period. Baseline older age, walking disability, receiving pension, and having 2+ hospital admissions within 12 months were also significantly associated with incident use of support services.
CONCLUSIONS: Development of bilateral visual impairment in this cohort was associated with greater likelihood of subsequent use of community or informal support services in 5 years, independent of physical comorbidities.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23688709     DOI: 10.1016/j.ajo.2013.04.002

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Health- and Vision-Related Quality of Life in a Randomized Controlled Trial Comparing Methotrexate and Mycophenolate Mofetil for Uveitis.

Authors:  Nicole K Kelly; Aheli Chattopadhyay; S R Rathinam; John A Gonzales; Radhika Thundikandy; Anuradha Kanakath; S Bala Murugan; R Vedhanayaki; Dean Cugley; Lyndell L Lim; Eric B Suhler; Hassan A Al-Dhibi; Caleb D Ebert; Elyse J Berlinberg; Travis C Porco; Nisha R Acharya
Journal:  Ophthalmology       Date:  2021-03-04       Impact factor: 14.277

2.  Visual impairment and ten-year mortality: the Liwan Eye Study.

Authors:  Lanhua Wang; Zhuoting Zhu; Jane Scheetz; Mingguang He
Journal:  Eye (Lond)       Date:  2020-10-19       Impact factor: 4.456

3.  The use of informal care by people with vision impairment.

Authors:  Ana Patricia Marques; Antonio Filipe Macedo; Laura Hernandez-Moreno; Pedro Lima Ramos; Thomas Butt; Gary Rubin; Rui Santana
Journal:  PLoS One       Date:  2018-06-07       Impact factor: 3.240

4.  The burden of neovascular age-related macular degeneration: a patient's perspective.

Authors:  Kimberly L Spooner; Cleopatra T Mhlanga; Thomas H Hong; Geoffrey K Broadhead; Andrew A Chang
Journal:  Clin Ophthalmol       Date:  2018-12-04

5.  Estimating the global cost of vision impairment and its major causes: protocol for a systematic review.

Authors:  Ana Patricia Marques; Jacqueline Ramke; John Cairns; Thomas Butt; Justine H Zhang; Hannah B Faal; Hugh Taylor; Iain Jones; Nathan Congdon; Andrew Bastawrous; Tasanee Braithwaite; Marty Jovic; Serge Resnikoff; Allyala Nandakumar; Peng Tee Khaw; Rupert R A Bourne; Iris Gordon; Kevin Frick; Matthew J Burton
Journal:  BMJ Open       Date:  2020-09-06       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.